Welcome to our dedicated page for Precision BioSciences news (Ticker: DTIL), a resource for investors and traders seeking the latest updates and insights on Precision BioSciences stock.
Precision BioSciences, Inc., based in Durham, North Carolina, is a pioneering biotechnology company dedicated to enhancing life through advanced genome editing. The company employs its proprietary genome editing platform, ARCUS, to develop innovative product candidates aimed at treating human diseases and offering solutions in food and agriculture.
ARCUS, distinguished by its compact size, enables the delivery of gene edits to a broader range of cells and tissues using both viral and non-viral methods. This versatility makes it a robust tool in Precision BioSciences' mission to address various health conditions and agricultural challenges.
The company has recently made significant strides in its projects, partnering with multiple organizations to expand its research and product development capabilities. These collaborations have been pivotal in propelling forward the potential applications of ARCUS technology.
Precision BioSciences is actively engaged in several cutting-edge projects that underscore its commitment to innovation. The company's financial health is reflected in its consistent investment in research and development, ensuring sustained growth and advancement in its technology.
Latest News:
- Source: iECURE, Inc.
- Source: Precision BioSciences, Inc.
- Source: Precision BioSciences
Precision BioSciences (NASDAQ: DTIL) reported a pivotal 2020, achieving significant advancements in its ARCUS genome editing and CAR T programs. The company announced a collaboration with Eli Lilly for developing gene therapies, receiving $100 million upfront. Financially, total revenues rose to $24.3 million, while R&D expenses increased to $98.1 million, reflecting growth in clinical programs. However, the net loss widened to $109 million, or $(2.09) per share. Key milestones for 2021 include initiating the PBCAR19B clinical trial and reporting interim data for multiple CAR T programs.
Precision BioSciences, Inc. (Nasdaq: DTIL) will release its fourth quarter and fiscal year 2020 financial results and a business update on March 18, 2021. The company focuses on improving lives through its ARCUS® genome editing platform, which enables the development of CAR T immunotherapy clinical candidates and gene correction therapies. These advancements aim to address genetic and infectious diseases lacking adequate treatment options. For more information, visit www.precisionbiosciences.com.
Precision BioSciences (Nasdaq: DTIL) announced participation in two upcoming virtual investor conferences on March 9, 2021. The first is the H.C. Wainwright Global Life Sciences Conference, featuring an on-demand fireside chat starting at 7:00 AM ET. The second is the Barclays Global Healthcare Conference, with a presentation scheduled for 10:55 AM ET. Both events will be accessible via the company's website, ensuring investors can stay informed.
Precision BioSciences (Nasdaq: DTIL) announced a significant publication in Molecular Therapy detailing three-year follow-up results from a study on PCSK9 gene editing via its ARCUS® platform.
The study demonstrated a long-term reduction of LDL cholesterol levels by up to 56% in nonhuman primates after a single treatment, with stable reductions in PCSK9 protein levels by 85%. This data supports the potential for a one-time therapeutic approach to familial hypercholesteremia and highlights the efficacy and safety of ARCUS technology.
Precision BioSciences (Nasdaq: DTIL), a clinical stage biotechnology company, announced its participation in the Guggenheim Healthcare Talks 2021 Oncology Day on February 11, 2021, at 2:00 PM ET. A live webcast of the presentation will be available on the company’s website in the Investors & Media section. Precision BioSciences is focused on improving life through its proprietary ARCUS genome editing platform, which aims to develop CAR T immunotherapy and gene correction therapies for genetic and infectious diseases.
Precision BioSciences (Nasdaq: DTIL) announced a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application covering its PBCAR19B product candidate aimed at treating relapsed/refractory Non-Hodgkin Lymphoma (NHL). The patent will encompass genetically-modified human T cells utilizing Precision's ARCUS genome editing platform, with an expected expiration date in April 2040. PBCAR19B is designed to enhance CAR T cell persistence by reducing rejection from T cells and natural killer cells. The Phase 1 clinical study is anticipated to commence by mid-2021.
Precision BioSciences announced that the FDA has accepted its Investigational New Drug (IND) application for PBCAR19B, a candidate for treating relapsed/refractory Non-Hodgkin Lymphoma (NHL).
This Phase 1 trial is set to evaluate the safety and effectiveness of PBCAR19B. The trial aims to identify the maximum tolerated dose and any adverse effects at varying dose levels.
CEO Matt Kane expressed optimism regarding PBCAR19B's potential to improve allogeneic CAR T cell persistence, alongside ongoing efforts with PBCAR0191.
DURHAM, N.C., Jan. 07, 2021 – Precision BioSciences, Inc. (Nasdaq: DTIL) announced the closure of its in vivo gene editing collaboration and exclusive license agreement with Eli Lilly, following regulatory clearance. The collaboration focuses on using Precision's ARCUS genome editing platform for up to six gene targets, including Duchenne muscular dystrophy. Precision receives $100 million upfront and has already received $35 million from share purchases. They are eligible for $420 million in milestones and royalties on product sales. Precision will lead pre-clinical research while Lilly handles clinical development.
Precision BioSciences, a clinical-stage biotechnology company (DTIL), announced that Matt Kane and Derek Jantz will present at the 39th Annual J.P. Morgan Healthcare Conference from January 11-14, 2021. The company's presentation is scheduled for January 13, 2021, from 2:00 - 2:40 p.m. ET. A live webcast of the event will be available on their website, with an archive accessible for 30 days post-presentation. Precision BioSciences is dedicated to advancing life through its ARCUS® genome editing platform, focusing on CAR T immunotherapy and gene correction therapies.
Precision BioSciences (Nasdaq: DTIL) announced the departure of Chief Financial Officer Abid Ansari after nearly five years, effective at the end of 2020, to pursue a new career opportunity. Alex Kelly, the Chief Corporate Affairs Officer, will serve as Interim CFO, while Shane Barton, Vice President and Corporate Controller, will be the interim principal accounting officer. CEO Matt Kane expressed gratitude for Ansari's contributions during a transformational phase for the company, emphasizing a focus on advancing their allogeneic CAR T cell therapy and in vivo gene correction pipelines.
FAQ
What is the current stock price of Precision BioSciences (DTIL)?
What is the market cap of Precision BioSciences (DTIL)?
What does Precision BioSciences, Inc. do?
Where is Precision BioSciences, Inc. located?
What is ARCUS?
What are some recent achievements of Precision BioSciences?
What is the focus of Precision BioSciences' current projects?
How does ARCUS differ from other genome editing tools?
Who are some partners of Precision BioSciences?
What kind of financial strategy does Precision BioSciences employ?
What is the significance of Precision BioSciences' work in agriculture?
How does Precision BioSciences contribute to human health?
